Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Express Scripts
Fuji
Cipla
McKesson
Healthtrust
Teva
UBS
Citi

Generated: June 22, 2018

DrugPatentWatch Database Preview

MIGRANAL Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Migranal, and when can generic versions of Migranal launch?

Migranal is a drug marketed by Valeant and is included in one NDA.

The generic ingredient in MIGRANAL is dihydroergotamine mesylate. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the dihydroergotamine mesylate profile page.
Drug patent expirations by year for MIGRANAL
Pharmacology for MIGRANAL
Ingredient-typeErgotamines
Drug ClassErgotamine Derivative
Medical Subject Heading (MeSH) Categories for MIGRANAL
Synonyms for MIGRANAL
(10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman mesylate
(10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman methanesulfonate
(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-BENZYL-2-HYDROXY-4-METHYL-5,8-DIOXO-3-OXA-6,9-DIAZATRICYCLO[7.3.0.0(2),?]DODECAN-4-YL]-6-METHYL-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(16),9,12,14-TETRAENE-4-CARBOXAMIDE; METHA
(4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),9,12(16),13-tetraene-4-carboxamide; metha
(4R,7R)-N-[(1S,2S,4R,7S)-7-BENZYL-2-HYDROXY-4-METHYL-5,8-DIOXO-3-OXA-6,9-DIAZATRICYCLO[7.3.0.0(2),?]DODECAN-4-YL]-6-METHYL-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(16),9,12,14-TETRAENE-4-CARBOXAMIDE; METHANES
(6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxa
(6aR,9R)-N-((2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate
11032-41-0
511-12-6 (Parent)
6190-39-2
81AXN7R2QT
9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotaman-3',6',18-trione mesylate
9,10-Dihydroergotamine mesylate
9,10-dihydroergotamine methanesulfonate
910882-41-6
AC1L2FO7
AC1LAOVT
AC1Q6WD6
ADYPXRFPBQGGAH-UMYZUSPBSA-N
AKOS024282478
AN-21195
ANW-42737
C33H37N5O5.CH4O3S
CCG-39548
CHEBI:59756
CHEMBL1200517
CHEMBL1396675
CS-2903
CTK8B3562
D 2763
D.H.E. 45
D02211
D0SP3D
D2633
DETMS
DHE-45
Dihydergot
Dihydroergotamine (mesylate)
Dihydroergotamine for peak identification, European Pharmacopoeia (EP) Reference Standard
Dihydroergotamine mesilate
Dihydroergotamine mesilate (JP17)
Dihydroergotamine mesilate, European Pharmacopoeia (EP) Reference Standard
Dihydroergotamine mesylate
Dihydroergotamine mesylate (USP)
Dihydroergotamine mesylate [USAN:USP]
Dihydroergotamine mesylate [USAN]
Dihydroergotamine mesylate, United States Pharmacopeia (USP) Reference Standard
Dihydroergotamine methanesulfonate
Dihydroergotamine methanesulfonate salt
Dihydroergotamine methanesulfonate salt, powder
Dihydroergotamine monomethanesulfonate
DIHYDROERGOTAMINE; METHANESULFONIC ACID
Dihydroergotoxin
DIHYDROERGOTOXINE
Dihytamine
DR003475
DR003476
EINECS 228-235-6
Ergoloid dihydroergotoxine
Ergoloid Mesylates (dihydroergotoxine)
Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy- 2'-methyl-5'-(phenylmethyl)-, (5'?,10?)-, monomethanesulfonate (salt)
Ergotamine, 9,10-dihydro-, monomethanesulfonate (salt)
Ergotamine, dihydro, methanesulfonate (salt)
Ergotoman-3',6',18-trione,9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, monomethanesulfonate (salt)
EU-0100357
HMS1920G16
HMS2094K05
HMS2231H03
HMS3261G15
HMS3266C22
HMS3369K10
HMS501N14
HY-B0670A
I14-101170
LP00357
LS-64558
MFCD00058615
mide methanesulfonate
MLS002153175
MLS002207048
MolPort-003-666-163
MT 300
N-{7-BENZYL-2-HYDROXY-4-METHYL-5,8-DIOXO-3-OXA-6,9-DIAZATRICYCLO[7.3.0.0(2),?]DODECAN-4-YL}-6-METHYL-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(16),9,12,14-TETRAENE-4-CARBOXAMIDE; METHANESULFONIC ACID
NCGC00261042-01
Neomigran
NSC-759848
NSC759848
Pharmakon1600-01500248
PL001844
PL041420
PL057923
Prestwick_746
rboxamide methanesulfonate(salt)
SCHEMBL40843
SCHEMBL40844
SMR001230668
SPECTRUM1500248
SR-01000075382
SR-01000075382-1
ST056346
Tox21_500357
TR-021291
TRA0034972
UNII-81AXN7R2QT
Z1544404034

US Patents and Regulatory Information for MIGRANAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant MIGRANAL dihydroergotamine mesylate SPRAY, METERED;NASAL 020148-001 Dec 8, 1997 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for MIGRANAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant MIGRANAL dihydroergotamine mesylate SPRAY, METERED;NASAL 020148-001 Dec 8, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Valeant MIGRANAL dihydroergotamine mesylate SPRAY, METERED;NASAL 020148-001 Dec 8, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Valeant MIGRANAL dihydroergotamine mesylate SPRAY, METERED;NASAL 020148-001 Dec 8, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Queensland Health
Cipla
Cerilliant
Argus Health
Harvard Business School
McKinsey
Covington
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.